https://doi.org/10.55788/b7806b7c
The problem with identifying patients likely to progress to psoriatic arthritis is that “it is not exactly a linear line,” said Prof. Coates [1]. “It is a process with different levels of disease progression and probably different stages of that disease. So how do we identify those populations with pre-psoriatic arthritis?”
Risk factors for psoriatic arthritis in patients with psoriasis
Based on current evidence, the risk of developing psoriatic arthritis is increased by a positive family history, higher psoriasis severity, longer psoriasis duration, presence of arthralgia, stiffness and fatigue, obesity (BMI>35), uveitis, and thyroid disease history [2]. Other risk factors include the site of psoriasis, hyperlipidaemia, depression, and smoking. It should be noted that people who did not develop psoriatic arthritis after a very long psoriasis duration were more likely not to develop the disease.
The PRESTO tool was developed to predict psoriatic risk based on 635 patients with psoriasis without psoriatic arthritis who were followed prospectively between 2006–2020 (mean follow-up of 7.7 years) [3]. Development of psoriatic arthritis within 1 year was predicted by younger age, male sex, family history of psoriasis, back stiffness, nail pitting, level of stiffness, and use of biologic medications. The 5-year risk was predicted by morning stiffness, psoriatic nail lesion, psoriasis severity, fatigue severity, pain severity, and use of systemic non-biologic medication/phototherapy.
Preventing psoriatic arthritis
“At the moment, we only treat when people get a psoriatic arthritis diagnosis,” said Prof. Coates [1]. But interventions should ideally happen earlier, during the subclinical or prodromal stages prior to clinical psoriatic arthritis. “The question is: if we intervene early, can we completely change the outcome and keep the disease under control?”
Lifestyle interventions are a potential way to prevent psoriatic arthritis. Prof. Coates presented unpublished data based on 2,604 patients with psoriasis from the UK Biobank longitudinal study [1]. These patients were asked to wear an accelerometer to track their physical activity and the addition of 1,000 steps per day reduced the risk of developing psoriatic arthritis by 10%. Furthermore, 1 h/day of moderate-to-vigorous physical activity was associated with a lower risk of developing psoriatic arthritis (HR 0.74; 95% CI 0.62–0.87).
In terms of pharmacological interventions, the IVEPSA study assessed secukinumab in 20 participants with moderate-to-severe psoriasis or with nail/scalp involvement and no psoriatic arthritis [4]. Most participants in this trial had arthralgia and inflammatory lesions determined by imaging. Following 24 weeks of treatment, secukinumab significantly improved arthralgia, synovitis, and bone mass in the distal radius, with no progression in erosion or enthesophytes.
Take-home message
“There is a huge potential with an easily identifiable pre-psoriatic arthritis population,” said Prof. Coates, but “we need to evaluate that risk more accurately and get the right group of people into the studies. Biologicals are likely to reduce risk, but the question truly is whether this is changing the evolution of the disease or masking the disease.” Finally, Prof. Coates said that “we need to know which drug is best and it might not be the same drug preventing disease that also treats the disease.”
- Coates LC. Can we prevent psoriatic arthritis? IFPA Conference 2024, 27–29 June, Stockholm, Sweden.
- Scher JU, et al. Nat Rev Rheumatol. 2019;15(3):153-166.
- Eder L, et al. Abstract 1612, ACR Convergence 2022, 10–14 November, Philadelphia, USA.
- Kampylafka E, et al. Arthritis Res Ther. 2019;21(1):178.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Diagnosing generalised pustular psoriasis Next Article
Improving outcomes in pregnancy and psoriatic disease »
« Diagnosing generalised pustular psoriasis Next Article
Improving outcomes in pregnancy and psoriatic disease »
Table of Contents: IFPA 2024
Featured articles
Multiple novel oral agents show promise in psoriasis
Advances in psoriasis treatment: topical therapies show promising results
Personalised Medicine and Genetics in Psoriatic Disease
How close are we to personalised medicine in psoriatic arthritis?
Genetic and immunological advances in risk assessment and treatment of psoriatic diseases
Using advances in the genetics of psoriatic disease to better predict treatment response
Comorbidities and Complications in Psoriatic Disease
Depression complicates the management of psoriatic disease
The unfavourable role of obesity in psoriatic disease
Managing obesity and fibromyalgia in psoriatic disease
Advances in Psoriasis Treatment
Multiple novel oral agents show promise in psoriasis
Biologics for psoriasis: towards oral therapies and less frequent dosing
Advances in psoriasis treatment: topical therapies show promising results
Special Populations and Psoriatic Disease
Improving outcomes in pregnancy and psoriatic disease
Towards prevention of psoriatic arthritis in patients with psoriasis
Diagnostic Challenges and Disease Management
Itch and pain are major components of psoriatic disease and require management
Can diet help with the management of psoriasis?
Biologics in psoriatic arthritis: where we are and where we are headed
Related Articles
December 1, 2023
Apremilast in early oligoarticular PsA: phase 4 study results
July 17, 2024
Improving outcomes in pregnancy and psoriatic disease
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com